As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Kairos Pharma (NYSE American: KAPA) presented new preclinical data at the ASCO 2025 Annual Meeting on its investigational small molecule GITR ligand agonist, KROS101. The study, titled “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” demonstrated KROS101’s dual mechanism of enhancing effector T cell activity while reducing immune-suppressive T reg cells. Results showed that KROS101 outperformed TRX518, a prior anti-GITR antibody, in promoting tumor infiltration, boosting cytotoxicity, and preventing T cell exhaustion. CEO Dr. John Yu emphasized the potential of KROS101 to advance cancer immunotherapy by simultaneously stimulating immune response and tumor destruction.
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill.
Kairos Pharma (NYSE American: KAPA) announced it will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman John Yu, MD, will host one-on-one meetings with investors from 9 a.m. to 3 p.m. ET.
Kairos Pharma (NYSE American: KAPA), announced it will present new data on KROS 101, a small molecule GITR ligand agonist, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster, titled “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” will be presented June 2 at McCormick Place in Chicago. Kairos CEO John Yu, M.D., highlighted the opportunity to share findings and advance discussions around KROS 101’s potential in optimizing cancer treatment.
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recent progress and strategic developments. The company is advancing two clinical trials for lead candidate ENV105 in prostate and EGFR-dependent non-small cell lung cancers, with safety and interim efficacy results expected in Q2 2025. Kairos is also developing KROS101, an immune response modulator, with recent data presented at key oncology conferences. Supported by non-dilutive government grants, an expanding trial network, and analyst coverage from firms including EF Hutton and HC Wainwright, Kairos emphasized its strong financial position and robust IP portfolio extending into the 2030s.
Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer. The study focuses on patients developing resistance to osimertinib, aiming to identify those who may benefit from early intervention with ENV105. The funding will support research in Dr. Neil Bhowmick’s lab and aligns with Kairos’ strategy to improve long-term outcomes through targeted therapy and precision monitoring.
Kairos Pharma, Ltd. (NYSE American: KAPA) is a clinical stage company involved in treating EGFR-driven lung cancer patients with ENV105 in combination with osimertinib after they fail to respond to single-agent osimertinib in a Phase 1 trial. Based on recent breakthroughs in understanding non-small cell lung cancer mechanism of resistance to first line osimertinib treatment, the U.S. Department of Defense (“DoD”) is providing $876,000 to advance a strategy to identify patients that are starting to develop resistance at an early stage. The grant was awarded to identify biomarkers for the Company’s clinical study to address the major challenge in achieving a lasting cure for lung cancer patients. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick’s laboratory to identify biomarkers of patients with non-small cell carcinoma who have developed resistance to Osimertinib. This will provide a means to identify those patients who will benefit from ENV105.
